EraGen Gets FDA OK for Herpes MDx Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – EraGen Biosciences has received US Food and Drug Administration clearance for its molecular test for herpes simplex virus, the firm said today.

The Madison, Wis.-based company said that its MultiCode-RTx HSV 1&2 Kit received 510(k) market clearance, which it said is the first molecular test for herpes simplex virus to be cleared by FDA. The test uses the firm's novel synthetic DNA base pair isoC:isoG, and detects and types HSV 1 and 2 DNA in vaginal lesions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.